title: The Year in Cardiology 2013: heart failure.
abstract: Heart failure has become a worldwide epidemic of the 21st century with increasing impact on healthcare systems. The 2012 ESC and 2013 ACCF/AHA guidelines have set the stage for current therapy to reduce mortality and morbidity. There is a dawn of hope for therapy of acute and diastolic heart failure; it has become clearer that patients benefit from mitral reconstruction and which patients benefit from heart failure management programmes; genetics and proteomics advance in great strides; competing concepts of cell therapy seem to spiral, hopefully upwards; and we can further nurture our hope for evidence-based individualized diagnostic and therapy.
authors.affiliation: Medizinische Klinik 1/Deutsches Zentrum für Herzinsuffizienz, Würzburg, Germany.
authors.forename: Georg
authors.initials: G
authors.lastname: Ertl
authors.forename: Frank
authors.initials: F
authors.lastname: Ruschitzka
mesh_terms: D006348:Cardiac Surgical Procedures / Q000639:trends; D002309:Cardiology / Q000639:trends*; D002316:Cardiotonic Agents / Q000627:therapeutic use; D006333:Heart Failure / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D006801:Humans; D057285:Precision Medicine / Q000639:trends; D013318:Stroke Volume / Q000502:physiology
chemical_list: D002316:Cardiotonic Agents
keywords: Heart failure